19.6 C
New York
Saturday, June 3, 2023

Momentum Is Strong For BridgeBio Pharma Inc. (NASDAQ: BBIO)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for BridgeBio Pharma Inc. (BBIO) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.01, or 0.07%, to $13.72. The BridgeBio Pharma Inc. has recorded 36,947 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $13.71 and fluctuated between $14.05 as its day high and $13.63 as its day low. The current market capitalization of BridgeBio Pharma Inc. is $2.24B. A total of 1.13 million shares were traded on the day, compared to an average of 3.22M shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, BBIO has seen 0 BUY and 4 SELL insider trades, representing the acquisition of 0 and the disposition of 358,192 shares. Over the last 12 months, there were 12 BUYs and 26 SELLs from insiders. Insiders purchased 311,759 shares during that period but sold 1,160,335.

In the most recent transaction, Kumar Neil sold 51,552 shares of BBIO for 14.01 per share on May 17. After the transaction, the CEO and President now owns 4,813,197 company shares. In a previous transaction on May 17, STEPHENSON BRIAN C sold 24,424 shares at 14.01 per share. BBIO shares that Secretary, Treasurer & CFO owns now total 36,408.

Among the insiders who sold shares, Kumar Neil disposed of 120,000 shares on May 03 at a per-share price of $14.18. This resulted in the CEO and President holding 1,012,722 shares of BBIO after the transaction. In another insider transaction, STEPHENSON BRIAN C sold 64,929 shares at $14.18 per share on May 03. Company shares held by the Secretary, Treasurer & CFO now total 36,408.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for BBIO in the last 3 months, the mean price target is $28.30 with high estimates of $40.00 and low estimates of $18.00. In terms of 52-week highs and lows, BBIO has a high of $19.94 and a low of $5.74.

As of this writing, BBIO has an earnings estimate of -$0.82 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.66 per share and a lower estimate of -$0.94. The company reported an EPS of -$0.92 in the last quarter, which was -8.20% lower than expectations of -$0.85.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BBIO’s latest balance sheet shows that the firm has $787.51M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $130.13M in liabilities at the time. Its Book Value Per Share was -$8.03, while its Total Shareholder’s Equity was -$865.58M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.90.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles